Literature DB >> 18534889

Impaired Trypanosoma cruzi-specific IFN-gamma secretion by T cells bearing the BV9 T-cell receptor is associated with local IL-10 production in non-lymphoid tissues of chronically infected mice.

Javier Vogt1, Catalina Dirney Alba Soto, Mariana Paula Mincz, Gerardo Ariel Mirkin.   

Abstract

The role of non-lymphoid tissue T cells expressing the BV9 family T-cell receptor (TCRBV9) was studied in mice chronically infected with the Trypanosoma cruzi. Heart and skeletal muscles had higher frequencies and ratios of CD8+ TCRBV9+ to CD4+ TCRBV9+ T cells than lymph nodes. Also, homing experiments of CFSE-labeled T cells showed preferential homing of TCRBV9+ T cells to heart tissue. In vitro proliferation assays showed higher [3H]thymidine uptake by non-lymphoid tissue TCRBV9+ T cells than lymph node TCRBV9+ T cells co-cultured with antigen-presenting cells (APC), in response to T. cruzi amastigote antigens (TcAg). Lymph node TCRBV9+ T cells secreted IFN-gamma and IL-10, but not IL-4, upon stimulation with TcAg in the presence of APC. Moreover, non-lymphoid tissue-derived TCRBV9+ T cells showed impairment of IFN-gamma, no IL-4 production, and higher levels of IL-10 secretion under the same conditions. Our results show that T. cruzi-specific IFN-gamma- and IL-10-producing TCR BV9+ T cells develop in the mouse lymph nodes during chronic infection with T. cruzi. Upon homing to non-lymphoid parasitized tissues, IFN-gamma secretion might subside due to the overt secretion of IL-10, of which TCRBV9+ T cells represent a significant source.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18534889     DOI: 10.1016/j.micinf.2008.04.013

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  6 in total

Review 1.  Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens.

Authors:  Joshua C Cyktor; Joanne Turner
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

2.  Interleukin 10 Polymorphisms as Risk Factors for Progression to Chagas Disease Cardiomyopathy: A Case-Control Study and Meta-Analysis.

Authors:  Alicia Grijalva; Lucia Gallo Vaulet; Roberto Nicolas Agüero; Analia Toledano; Marikena Guadalupe Risso; Juan Quarroz Braghini; David Sosa; Paula Ruybal; Silvia Repetto; Catalina Dirney Alba Soto
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

3.  Specific humoral immunity versus polyclonal B cell activation in Trypanosoma cruzi infection of susceptible and resistant mice.

Authors:  Marianne A Bryan; Siobhan E Guyach; Karen A Norris
Journal:  PLoS Negl Trop Dis       Date:  2010-07-06

4.  Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease.

Authors:  Ágata C Cevey; Gerardo A Mirkin; Martín Donato; María J Rada; Federico N Penas; Ricardo J Gelpi; Nora B Goren
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2017-10-07       Impact factor: 4.077

Review 5.  T-cell receptor variable region usage in Chagas disease: A systematic review of experimental and human studies.

Authors:  Thaiany Goulart de Souza-Silva; Kenneth J Gollob; Walderez O Dutra
Journal:  PLoS Negl Trop Dis       Date:  2022-09-15

6.  Elevated serum levels of macrophage migration inhibitory factor are associated with progressive chronic cardiomyopathy in patients with Chagas disease.

Authors:  Romina A Cutrullis; Patricia B Petray; Edgardo Schapachnik; Rubén Sánchez; Miriam Postan; Mariela N González; Valentina Martín; Ricardo S Corral
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.